First patient dosed in landmark Menstrual Migraine study
Asarina Pharma AB (publ) (ASAP: FN Stockholm) has administered the first dose in its Phase IIa trial of a new, preventative treatment for menstrual migraine. Sepranolone is the first woman-only migraine treatment, specifically targeting menstrual migraine.
Asarina Pharma AB (publ) Interim Report Q3 2019 released
Asarina Pharma CEO Peter Nordkild: “During an intense third quarter we achieved some important milestones. We enrolled the last patient in our landmark PMDD study, received FDA approval for our IND in menstrual migraine and included the first patient in our menstrual migraine study. After the end of the quarter a new directed share issue…
Asarina Pharma: Redeye reports positively on new directed share issue
October 25, 2019: Redeye: “We see Asarina Pharma as one of the truly undiscovered biotech cases on the Scandinavian stock markets. We argue that the prospects for showing good results in its PMDD Phase IIb Study are good, which is not at all reflected in the stock price at present.”
Asarina Pharma has completed a directed share issue of approximately SEK 48 million
Asarina Pharma AB (publ) (Nasdaq First North Growth Market: ASAP) (”Asarina Pharma” or the “Company”) today announces that the Company has successfully completed a directed share issue of 2,159,148 shares, corresponding to approximately SEK 48 million. In addition, existing shareholders have due to high demand sold 764,329 existing shares, corresponding to approximately SEK 17 million,…
Asarina Pharma intends to carry out a directed share issue
Asarina Pharma AB (publ) (Nasdaq First North Growth Market: ASAP) (”Asarina Pharma” or the “Company”) today announces its intention to execute a directed share issue to institutional investors (the “Issue”).
Privacy & Cookies Policy